The efficacy of temozolomide for recurrent glioblastoma multiforme

Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis

(2017) Eric T. Wong et al.   Journal of the National Comprehensive Cancer Network

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

(2011) D.-S. Kong et al.   NEURO-ONCOLOGY

Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma

(2010) Michael Brada et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

(2010) James R. Perry et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma

(2010) Ufuk Abacioglu et al.   JOURNAL OF NEURO-ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Extended-schedule dose-dense temozolomide in refractory gliomas

(2009) A. Berrocal et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas

(2008) Casilda Balmaceda et al.   CANCER

A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma

(2008) Bart Neyns et al.   CANCER INVESTIGATION